Dr. Tedder is a Founder of Angelica. He is the Alter Geller Professor for Research in Immunology at Duke University Medical Center. Dr. Tedder is a world-recognized leader in the fields of B lymphocyte biology and regulation. He currently has 380 publications and a portfolio of 25 issued patents related to B cells and their products including CD19, CD20, CD22, CD83, and L-selectin. Dr. Tedder received his Ph.D. from the University of Alabama in Birmingham, and was a faculty member at Dana-Farber Cancer Institute and Harvard Medical School before joining Duke University as its founding Chairman of Immunology. Most recently, Dr. Tedder founded Cellective Therapeutics, a Gaithersburg, MD biotherapeutics company spun out of Duke University in 2004 and subsequently acquired by MedImmune in 2006.
Dr. Ronald Levy is Chief of the Division of Oncology at Stanford University. He obtained his bachelor's degree in biochemistry from Harvard University in 1963 and his medical degree from Stanford University in 1968. He is an elected member of the National Academy of Sciences and the Institute of Medicine. Dr. Levy's research has focused for more than 20 years on monoclonal antibodies to B cells. He was the first to successfully treat human lymphoma with a monoclonal antibody, and went on to make important contributions to the development of rituximab (Rituxan®), for the treatment of patients with resistant low-grade lymphomas. Dr. Levy has published over 270 articles in the fields of oncology and immunology. Dr. Levy has received international acclaim for his work using the body's own arsenal to fight cancer. In 1982 he shared the first Armand Hammer Award for Cancer Research, and was later awarded the Ciba-Geigy/Drew Award in Biomedical Research, the American Society of Clinical Oncology Karnofsky Award, the General Motors Charles Kettering Prize, the Key to the Cure Award by the Cure for Lymphoma Foundation, the Medal of Honor by the American Cancer Society, the Evelyn Hoffman Memorial Award by the Lymphoma Research Foundation of America, the 2004 Damashek Prize from the American Society of Hematology, and the King Faisal International Prize.
Nam Hoang Dang, MD, PhD, is Professor of Medicine and Deputy Chief of the Division of Hematology/Oncology at the University of Florida, as well as Director of the University of Florida Cancer Center Clinical Trial Office. He formerly held leadership positions at The University of Texas MD Anderson Cancer Center and Nevada Cancer Institute. Dr Dang's research interest is in the identification of novel targets and the development of novel cancer therapies through preclinical and clinical trials. Specifically, he has conducted numerous clinical studies investigating the effect of immunoconjugates in hematologic malignancies, including denileukin diftitox (Ontak®). He has published over 100 original research articles, reviews and book chapters. After receiving his undergraduate degree in Biochemical Sciences magna cum laude at Harvard University, Dr. Dang received a PhD in Immunology from Harvard and his medical degree magna cum laude from Harvard Medical School, Dr. Dang subsequently performed his internship and residency in Internal Medicine at Massachusetts General Hospital, and his fellowship in Medical Oncology at Dana-Farber Cancer Institute.